Diabetes drug metformin could boost lung cancer treatment in new trial
NCT ID NCT05445791
First seen Apr 23, 2026 · Last updated Apr 29, 2026 · Updated 3 times
Summary
This phase 3 study tests whether adding the diabetes drug metformin to standard targeted therapy (tyrosine kinase inhibitors) can help control advanced non-small cell lung cancer with EGFR mutations. About 312 adults with stage IIIB or IV lung cancer will receive either metformin or a placebo alongside their usual treatment. The goal is to see if the combination delays cancer progression and improves survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Instituto Nacional de Cancerologia
RECRUITINGMexico City, 14080, Mexico
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.